Allergic rhinitis
Conditions
Interventions
Experimental group:Standardized sublingual specific immunotherapy is used with concomitant symptomatic agents as needed
Control group:Use only symptomatic medications as needed
Sponsors
Chengdu Women and Children's Central Hospital
Eligibility
Sex/Gender
All
Age
4 Years to 12 Years
Inclusion criteria
Inclusion criteria: (1) Those who have been diagnosed with AR and do not have other allergic diseases such as AD and AS; (2) 4-12 years old, male or female; (3) Allergen test results: Dust mite was positive, which was closely related to clinical symptoms and was the main allergen; (4) Willing to receive immunotherapy, able to comply with the protocol, and receive telephone follow-up.
Exclusion criteria
Exclusion criteria: (1) Clinically diagnosed non-AR patients; (2) Have a history of drug allergies; (3) Those who are being treated with ß2-blockers or ACE inhibitors; (4) Patient has undergone major surgical surgery within 4 weeks prior to enrollment; (5) Patients who have used systemic corticosteroids (oral, intravenous, etc.) within 4 weeks before enrollment, and can be enrolled after the patient has stopped taking the drug for more than 4 weeks; (6) Patients with factors that affect drug absorption, distribution, metabolism, excretion, etc., such as liver and kidney insufficiency; (7) Participated in other drug trials within three months; (8) Patients with poor compliance with the study protocol; (9) Any situation that the investigator considers unsuitable to participate in the trial;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total nasal symptoms score;Total medication score;Visual analogue scale;ahinoconjunctivitis quality of life questionnaire; | — |
Countries
China
Contacts
Public ContactLiu Min
Chengdu Women and Children's Central Hospital
Outcome results
None listed